ClinicalTrials.gg
RecruitingNCT07937254JAR2203-SAD-P1Updated Nov 16, 2026

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of JAR-2203 in Healthy Participants With Elevated Plasma Lipoprotein(a)

A Phase 1 interventional study of JAR-2203 and Placebo in Lipid Metabolism Disorders, Healthy Volunteers - Male and Female and Hyperlipoproteinemia(a), sponsored by Beijing Jiake Ruikang Pharmaceutical Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionHyperlipoproteinemiasRegistry: Lipid Metabolism DisordersReclassifiedWhy we changed it
Registry
Lipid Metabolism Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hyperlipoproteinemias
Why
  1. The study's listed conditions name Hyperlipoproteinemias, a narrower term within Lipid Metabolism Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Beijing Jiake Ruikang Pharmaceutical Technology Co., Ltd. · Phase 1, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and effects on Lp(a) of single ascending doses of JAR-2203 in healthy adults with elevated Lp(a).

Read the detailed description

JAR-2203 is an investigational small interfering RNA (siRNA) targeting LPA mRNA to reduce plasma lipoprotein(a) [Lp(a)] levels. This first-in-human, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of JAR-2203 in healthy participants with elevated Lp(a). Approximately 44 participants will be enrolled across six sequential dose cohorts, with dose escalation based on review by a Safety Review Committee.

02

Conditions studied

  • Lipid Metabolism Disorders
  • Healthy Volunteers - Male and Female
  • Hyperlipoproteinemia(a)

Browse trials for

Keywords

  • siRNA
  • Lipoprotein(a)
  • Hyperlipoproteinemia
  • Residual risk
  • Atherosclerosis
  • JAR-2203
  • small interfering RNA
  • Lp(a)
  • Phase 1
  • single ascending dose
  • healthy participants
03

In context

Hyperlipoproteinemias Reclassified

35 studies on the registry are indexed under Hyperlipoproteinemias; 6 are open to participants now.

This study's planned enrollment of 44 is below the median of 84 across 29 interventional studies indexed under Hyperlipoproteinemias.

Browse Hyperlipoproteinemias studies →

Lead sponsor

This is the only study on the registry with Beijing Jiake Ruikang Pharmaceutical Technology Co., Ltd. as lead sponsor.

Compared within Hyperlipoproteinemias, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lipid Metabolism Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult male or female participants aged 18-60 years (inclusive) at the time of signing the form (ICF).
  • At screening, male participants must have a body weight ≥ 50 kg, female participants must have a body weight ≥ 45 kg, and (BMI) must be 18-28 kg/m² (inclusive).
  • At screening, lipoprotein(a) [Lp(a)] ≥ 30 mg/dL.
  • Male participants and female participants of must agree to use highly effective measures throughout the entire study period. Male participants must have no plan to donate sperm; female participants of childbearing potential must have no plan to become pregnant, donate eggs, or undergo oocyte cryopreservation. Female participants must not have had unprotected sexual intercourse within 14 days before screening.
  • Voluntarily sign the ICF and be able to comply with the relevant study requirements and all restrictions during the study period.

Exclusion criteria

Exclusion Criteria:

  • History of diseases involving the neuropsychiatric, cardiovascular, respiratory, gastrointestinal, urinary, endocrine/metabolic, immune, musculoskeletal, or hematologic systems, as judged by the investigator.
  • Any clinically significant abnormal findings on physical examination, vital signs, , or laboratory tests, as judged by the investigator.
  • Systolic blood pressure ≥ 140 mmHg or \< 90 mmHg, or diastolic blood pressure ≥ 90 mmHg or \< 50 mmHg.
  • Fridericia- interval (QTcF) > 450 ms.
  • Positive serological results for , antibody (HCV-Ab), antibody (HIV-Ab), or Treponema pallidum antibody (Anti-TP). HBV positivity is defined as either (1) positive HBsAg or (2) positive HBcAb with negative HBsAb.
  • (ALT) or aspartate aminotransferase (AST) > (ULN); gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), or total (TBiL) > 1.5 × ULN.
  • Estimated (eGFR) \< 90 mL/min/1.73 m².
  • Total cholesterol (TC) or low-density lipoprotein cholesterol (LDL-C) > 1.2 × ULN; triglycerides (TG) > 2.3 mmol/L.
  • History of clinically significant , intolerance, or allergic reactions to any drugs, oligonucleotides, foods, or other substances, as judged by the investigator.
  • Acute febrile illness or evidence of active infection within 7 days prior to screening.
  • Administration of any medicinal product within 14 days prior to screening that, in the investigator's judgment, may potentially affect the evaluation outcomes of this study.
  • Receipt of any within 1 month before screening, or planned receipt of any live vaccine during the study period.
  • Any surgery within 12 months prior to screening, or planned surgery during the study period.
  • History of alcohol or drug abuse within 1 month prior to screening that, in the investigator's judgment, may potentially affect the evaluation outcomes of this study (alcohol consumption > 14 units/week; 1 unit of alcohol = 350 mL of beer, 150 mL of wine, or 30 mL of spirits).
  • Positive result on breath alcohol test, urine cotinine test, or urine drug screen at screening.
  • Participation as a subject in any pharmaceutical clinical trial within 3 months prior to screening; receipt of any siRNA therapy within 12 months prior to screening; or receipt of any antisense oligonucleotide therapy within 6 months prior to screening.
  • Blood loss or blood donation ≥ 400 mL, or donation of blood products ≥ 2 units, within 3 months prior to screening.
  • Unwilling to abstain from smoking, alcohol consumption, caffeine-containing foods or beverages, strenuous exercise, or other behaviors that may affect drug absorption, distribution, metabolism, and excretion from 24 hours prior to dosing throughout the entire study period.
  • Pregnant or lactating female participants; female participants of with a positive serum HCG test prior to dosing; or participants of who are unable or unwilling to use investigator-approved measures throughout the entire study period as instructed by the investigator.
  • History of intolerance to subcutaneous injection, or presence of scars (e.g., surgical or burn scars) at the planned subcutaneous administration site.
  • Poor peripheral venous access.
  • Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this clinical study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    JAR-2203

    Participants who receive a single subcutaneous injection of JAR-2203.

    Drug: JAR-2203

  • Placebo comparator
    Placebo

    Participants who receive a single subcutaneous injection of placebo.

    Drug: Placebo

Interventions

  • DrugJAR-2203

    JAR-2203 solution for injection given as a single subcutaneous injection; planned dose levels are 7.5, 30, 75, 150, 225, and 300 mg.

  • DrugPlacebo

    Placebo for injection given as a single subcutaneous injection at a volume matched to the active treatment.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)

    An adverse event is any untoward medical occurrence in a clinical trial participant. A TEAE is any event with onset after administration of the first dose of investigational product and up to and including the end of the study. Clinically significant changes in vital signs, 12-lead electrocardiograms (ECGs), and safety laboratory analytes are included as TEAEs. Severity is graded using NCI-CTCAE v6.0.

    Time frame: From first dose until the end of the study (through Day 169).

Secondary outcomes

  1. Maximum Observed Concentration (Cmax) of JAR-2203

    Plasma concentrations of JAR-2203 will be measured.

    Time frame: Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

  2. Time to Reach Maximum Concentration (Tmax) of JAR-2203

    Plasma concentrations of JAR-2203 will be measured.

    Time frame: Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

  3. Terminal Elimination Half-life (t1/2) of JAR-2203

    Plasma concentrations of JAR-2203 will be measured.

    Time frame: Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

  4. Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC0-24h) of JAR-2203

    Plasma concentrations of JAR-2203 will be measured.

    Time frame: Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

  5. Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of JAR-2203

    Plasma concentrations of JAR-2203 will be measured.

    Time frame: Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

  6. Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of JAR-2203

    Plasma concentrations of JAR-2203 will be measured.

    Time frame: Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

  7. Apparent Total Clearance (CL/F) of JAR-2203

    Plasma concentrations of JAR-2203 will be measured.

    Time frame: Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

  8. Apparent Volume of Distribution (Vz/F) of JAR-2203

    Plasma concentrations of JAR-2203 will be measured.

    Time frame: Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

  9. Urinary Excretion Parameters of JAR-2203 (Cohort 5 only)

    Cumulative amount excreted in urine (Ae), cumulative fraction excreted in urine (Fe), and renal clearance (CLR).

    Time frame: Predose and at 0-6, 6-12,12-24 and 24-48(Day 2) hours postdose

  10. Change From Baseline in Plasma Lipoprotein(a) [Lp(a)] Levels

    Change from baseline in plasma Lp(a) by cohort and scheduled time points.

    Time frame: Predose (within 60 minutes before dosing), at 12, 24 (Day 2), and 48 (Day 3) hours postdose, and at Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169.

  11. Percent Change From Baseline in Plasma Lipoprotein(a) [Lp(a)] Levels

    Percent change from baseline in plasma Lp(a) by cohort and scheduled time points.

    Time frame: Predose (within 60 minutes before dosing), at 12, 24 (Day 2), and 48 (Day 3) hours postdose, and at Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169.

  12. Change From Baseline in Other Lipid and Lipoprotein Parameters

    Change from baseline in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and triglycerides (TG).

    Time frame: Predose (within 60 minutes before dosing), at 12, 24 (Day 2), and 48 (Day 3) hours postdose, and at Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169.

Other outcomes

  1. Immunogenicity

    Incidence of anti-drug antibodies (ADA) and, if applicable, neutralizing antibodies (NAb).

    Time frame: Predose (within 60 minutes before dosing) and at Days 15, 29, and 57.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) from this study will not be shared. This is an early-phase study in a small number of healthy participants, and the sponsor does not expect the limited participant-level data to provide meaningful additional scientific value beyond the aggregated results that will be reported. The data also contain proprietary information regarding an investigational product.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Jul 2027, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 16, 2026
StartActual
Oct 19, 2026
Primary completionEst.
Jul 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937254
Lead sponsor
Beijing Jiake Ruikang Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Oct 19, 2026
Primary completion
Jul 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Shuya Li, MD
Contact
shuyali85@163.com
+8613601367028

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion